论文部分内容阅读
巴黎消息:波士顿DanaFarber癌症研究所的ThomasErvin医师说,在局部手术和/或放射治疗之前采用多种药物诱导化学疗法可使晚期头颈癌患者的预期无病存活期增加一倍。一项包括114名头部和颈部Ⅲ期或Ⅳ期鳞状细胞癌患者的研究表明,接受诱导化疗病人的5年总存活率为29％,而无病存活率为24％。Ervin说:“以上的5年存活率与相同类型病人预期的2年无病存活率相似,这表明存活时间大约增加了一倍。”波士顿研究项目中的所有病人在接受放疗和/或手术治疗之前进行了两个28天周期的诱导化疗。然后将诱导化疗有效者随机分为两组试验,一组再进行三个周期的化疗,另一组不进行化疗。
PARIS: Dr. Thomas Ervin of the DanaFarber Cancer Institute in Boston said that using multiple drug-induced chemotherapy before local surgery and/or radiation therapy can double the expected disease-free survival of patients with advanced head and neck cancers. A study of 114 patients with head and neck stage III or IV squamous cell carcinoma showed that the 5-year overall survival rate for patients receiving induction chemotherapy was 29%, and the disease-free survival rate was 24%. Ervin said: “The above five-year survival rate is similar to the expected 2-year disease-free survival rate of the same type of patients, which indicates that survival time has roughly doubled.” All patients in the Boston Research Project were treated with radiation and/or surgery Two induction cycles of induction chemotherapy were performed before. Then the effective induction chemotherapy was randomly divided into two groups of trials, one group was followed by three cycles of chemotherapy, and the other group was not treated with chemotherapy.